

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Diagnostics Advisory Committee (DAC)

### Minutes of the Meeting on 10 February 2016, 10:30-16:30

Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BD

#### Present for PIGF based testing to help diagnose suspected pre-eclampsia

#### Standing Committee members:

Professor Adrian Newland (Chairman)  
Professor Christopher Hyde  
Mr David Evans  
Dr Dermot Neely  
Professor Erika Denton  
Mrs Gail Norbury  
Mr John Hitchman  
Dr Mark Kroese  
Dr Michael Messenger  
Mr Paul Weinberger  
Dr Phil Chambers  
Dr Simon Fleming  
Dr Sue Crawford

#### Standing Committee apologies:

Prof Anthony Wierzbicki  
Dr Deirdre Ryan  
Professor Mark Sculpher  
Dr Peter Naylor  
Professor Ron Akehurst  
Dr Steve Edwards  
Dr Steve Thomas

#### NICE staff in attendance:

Mirella Marlow, Programme Director, DAP  
Carla Deakin, Associate Director, DAP  
Sarah Byron, Technical Adviser, DAP  
Frances Nixon, Technical Analyst, DAP  
Robert Fernley, Project Manager, DAP  
Nick Lowe, Administrator, DAP  
Christopher Pomfrett, Technical Adviser, MTEP

#### Observing:

Ciara Donnelly, Business Analyst, NICE

Elaine Chesworth, Medical Technology Implementation Manager, NICE  
Linda Granger, Senior Medical Editor, NICE

**1. Introduction to the meeting**

The Chair welcomed Committee members, observers and members of the public.

Apologies were noted.

**2. Code of conduct for members of the public attending the meeting**

The Chairman explained the code of conduct to the members of the public attending this meeting.

**3. Any other business**

No other business was offered.

**4. Minutes from the last Committee meeting**

The Committee agreed the minutes from the 1 December 2015 Committee meeting.

**5. NICE's advisory body guide to declaring a conflict of interest**

The Chairman drew the Committee's attention to NICE's Advisory Body Quick Guide for declaring conflicts of interest, the selection and routing criteria and the equalities statement.

**PIGF based testing to help diagnose suspected pre-eclampsia**

**External Assessment Group representatives: SHTAC**

Geoff Frampton, Senior Research Fellow,  
Micah Rose, Research Fellow,

**Specialist Committee members:**

Dr Jenny Myers, Senior Lecturer/Consultant Obstetrician  
Professor Jimmy Walker, Professor, University Department Obstetrics  
and Gynaecology  
Dr Nigel Simpson, Senior Lecturer and Honorary Consultant

**Specialist Committee members apologies:**

Mrs Ann-Marie Barnard, Lay Specialist Committee member  
Mrs Suzanne Thomas, Midwifery lead for the Manchester Placenta Clinic  
and St Mary's Rainbow Clinic  
Mr David Wells, Pathology General Manager  
Professor Jimmy Walker, Professor of Obstetrics and Gynaecology

## **PART 1 AND PART 2 (open and closed parts of the meeting).**

### **Part 1 – Open session**

The Chair welcomed representatives from Alere International Ltd, Perkin Elmer, Roche Diagnostics & Thermofisher Scientific, .

There were no public attendees.

The Chair asked Committee members to declare any relevant interests.

- Simon Richards declared a personal pecuniary interest; this meant he was unable to take part in the meeting.
- Michael Messenger declared a non-personal non-specific pecuniary interest, this did not preclude him from taking part in the meeting.

The Committee proceeded to discuss the comments made during the public consultation for the PIGF based testing to help diagnose suspected pre-eclampsia topic.

The Committee was asked if there were any specific equality issues to consider in relation to this assessment.

The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.

The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

The Chair thanked the manufacturer representatives for their attendance, participation and contribution to the meeting.

### **End of Part 1**

### **Part 2 – closed session**

Agreement on the content of the Diagnostic Guidance Document (DGD) was discussed by the committee.

### **End of Part 2**

**PRESENT: ImmunoCAP ISAC 112 and Microtest for multiplex allergen testing**

**Standing Committee members:**

Professor Adrian Newland (Chairman)  
Professor Christopher Hyde  
Mr David Evans  
Dr Dermot Neely  
Professor Erika Denton  
Mrs Gail Norbury  
Mr John Hitchman  
Dr Mark Kroese  
Dr Michael Messenger  
Mr Paul Weinberger  
Dr Phil Chambers  
Dr Simon Fleming  
Dr Simon Richards  
Dr Sue Crawford

**Standing Committee apologies:**

Professor Anthony Wierzbicki  
Dr Deirdre Ryan  
Professor Mark Sculpher  
Dr Peter Naylor  
Professor Ron Akehurst  
Dr Steve Edwards  
Dr Steve Thomas

**NICE staff in attendance:**

Mirella Marlow, Programme Director, DAP  
Carla Deakin, Associate Director, DAP  
Sarah Byron, Technical Analyst, DAP  
Rebecca Albrow, Technical Analyst, DAP  
Robert Fernley, Project Manager, DAP  
Nick Lowe, Administrator, DAP  
Christopher Pomfrett, Technical Adviser, MTEP

**Observing:**

Ciara Donnelly, Business Analyst, NICE  
Elaine Chesworth, Medical Technology Implementation Manager, NICE  
Linda Granger, Senior Medical Editor, NICE

**6. Introduction to the meeting**

The Chair welcomed Committee members, observers and members of the public.

Apologies were noted.

**7. Code of conduct for members of the public attending the meeting**

The Chairman explained the code of conduct to the members of the public attending this meeting.

**8. Any other business**

No other business was offered.

**9. Minutes from the last Committee meeting**

The Committee agreed the minutes from the 1 December 2015 Committee meeting.

**10. NICE's advisory body guide to declaring a conflict of interest**

The Chairman drew the Committee's attention to NICE's Advisory Body Quick Guide for declaring conflicts of interest, the selection and routing criteria and the equalities statement.

**ImmunoCAP ISAC 112 and Microtest for multiplex allergen testing**

**External Assessment Group representatives: KSR**

Marie Westwood, Review Manager

**Specialist Committee members:**

Dr Anthony Rowbottom, Consultant Clinical Immunologist,

Mr Boaz Gaventa, Lay Specialist Committee member

Dr Isabel Skypala, Consultant Allergy Dietitian & Clinical lead for food allergy

Dr Paul Turner, Honorary Consultant in Paediatric Allergy & Immunology

Roisin Fitzsimons, Nurse Consultant in paediatric allergy

**Specialist Committee members apologies:**

Mrs Jane Green, Lay Specialist Committee member

Professor Michael Arden-Jones, Associate Professor/ Consultant Dermatologist

**PART 1 AND PART 2 (open and closed parts of the meeting).**

**Part 1 – Open session**

The Chair welcomed representatives from ThermoFisher Scientific.

There were no public attendees.

The Chair asked Committee members to declare any relevant interests.

- Michael Messenger declared a non-personal non-specific pecuniary interest, this did not preclude him from taking part in the meeting.

The Committee proceeded to discuss the comments made during the public consultation for the ImmunoCAP ISAC 112 and Microtest for multiplex allergen testing topic.

The Committee was asked if there were any specific equality issues to consider in relation to this assessment.

The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.

The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

The Chair thanked the manufacturer representatives for their attendance, participation and contribution to the meeting.

**End of Part 1**

**Part 2 – closed session**

Agreement on the content of the Diagnostic Guidance Document (DGD) was discussed by the committee.

**End of Part 2**

**Date, time and venue of next meeting**

15 June 2016 10:00 – 16:30 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BD